2H51.F Ocugen Inc

Healthcare Biotechnology Frankfurt Exchange
0.8800 EUR
Close of Nov 12, 2026
0.6380 2.35
Market cap
EUR 299M
P/E
-
P/B
75.99x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is 2H51.F undervalued?

Graham number

The Graham number of Ocugen Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Ocugen Inc fundamental analysis

No fundamental analysis for Ocugen Inc yet.

Ocugen Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Ocugen Inc

Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the…

Full company profile